Misinformation Analysis

Why this page exists

Peptide content online is unusually noisy. Products are mislabeled, results are staged, safety is asserted without data, and financial relationships go undisclosed. The patterns are repetitive enough to learn, and learning them is more durable protection than memorizing which sellers are currently reputable.

Inaccurate labels

• Non-peptides sold as peptides — HCG is a glycoprotein hormone; Danuglipron is a small molecule; neither is a peptide.
• Blended or renamed products where the proprietary name obscures what is actually in the vial.
• Milligram amounts stated without accounting for water content or salt form, which changes the actual active dose.
• "Pharmaceutical grade" and "FDA-registered" used as substitutes for approval language.
• Dosing instructions printed on material simultaneously labeled Research Use Only — an internal contradiction, not a convenience.

Exaggerated transformations

• Lighting, posing, pump, tan, and dehydration account for a large share of dramatic before-and-after pairs.
• Undisclosed concurrent interventions — a calorie deficit, a new training program, anabolic steroids, or another medication — are frequently the actual cause.
• Timeframes compressed or omitted so a multi-year change reads as an eight-week result.
• Survivorship bias: the people who saw nothing do not post.
• Any single anecdote, however sincere, is an uncontrolled sample of one.

Unsupported safety claims

• "No side effects" — absence of reported harm in small, short, uncontrolled use is not evidence of safety.
• "Natural, so it's safe" — endogenous molecules at supraphysiologic doses are pharmacology, not nutrition.
• "Thousands of users, no problems" — self-selected reporting cannot detect uncommon or delayed harms.
• Extrapolating rodent safety data to humans, or short-trial safety to years of use.
• Silence on the contraindications that do exist — cancer history with GH-axis compounds, pancreatitis or medullary thyroid carcinoma history with incretins, and drug interactions across the board.

Misleading influencer content

• Undisclosed affiliate links, discount codes, or equity stakes — the FTC requires clear and conspicuous disclosure of material connections.
• Protocol advice from people with no clinical training and no accountability for outcomes.
• Citation laundering: a study linked to support a claim it does not actually make, or an animal study presented as human evidence.
• Scarcity and urgency framing around a compound that has no approved indication.
• Comment sections curated to remove reports of adverse effects.

A quick verification routine

• Identify the exact compound and its regulatory category before anything else.
• Find the primary source and confirm it says what the claim says.
• Check design, population, dose, route, and duration for relevance to the claim.
• Ask who benefits financially from you believing it.
• Ask what evidence would change the claim — if nothing could, it is not an evidence-based claim.